Related Experiment Video
Updated: Aug 8, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells
A J McIlwrath1, V G Brunton, R Brown
1CRC Department of Medical Oncology, CRC Beatson Laboratories, Glasgow, UK.
Abstract:
We have analysed the cell-cycle arrests and cytotoxicity of the A2780 human ovarian cell line in response to geldanamycin, a benzoquinoid ansamycin that can inhibit tyrosine kinases. Geldanamycin causes a dose-dependent G2 arrest and reversible inhibition of entry into the S phase in A2780 cells. After a 3-h exposure to 0.1 microM geldanamycin, the cells show an increase in accumulation of p53 protein that is maximal at 24 h after drug exposure. Increased p53 levels can be induced in cells by DNA-damaging agents; however, using alkaline elution and sister chromatid exchange assays we detect no DNA damage induced by geldanamycin. Using dominant negative mutant TP53 transfectants of A2780 we have analysed the possible dependence of geldanamycin-induced cell-cycle arrests on the presence of functional p53. We observe no difference in cell-cycle arrests in mutant p53 transfectants known to have the p53-DNA damage-response pathway inactivated as compared with vector-alone controls. Similarly, we observe no difference in clonogenic resistance to the cytotoxicity of geldanamycin in these cells. These results suggest that geldanamycin can induce increased p53 protein by a mechanism not involving DNA damage. Furthermore, the cell-cycle arrests and cytotoxic effects of geldanamycin in these cells are not mediated by p53-dependent pathways.
Insights
Geldanamycin causes cell cycle arrest and increases p53 protein in ovarian cancer cells without causing DNA damage. These effects are independent of the p53 pathway, suggesting novel therapeutic mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Geldanamycin is a tyrosine kinase inhibitor with known cytotoxic effects.
- The role of p53 in mediating geldanamycin's effects on ovarian cancer cells is not fully understood.
Purpose of the Study:
- To investigate the effects of geldanamycin on cell cycle progression and cytotoxicity in A2780 human ovarian cancer cells.
- To determine if DNA damage or p53-dependent pathways mediate these effects.
Main Methods:
- A2780 cells were treated with geldanamycin.
- Cell cycle analysis was performed.
- p53 protein accumulation was measured.
- DNA damage was assessed using alkaline elution and sister chromatid exchange assays.
- Cells with inactivated p53-DNA damage-response pathway were used to evaluate p53 dependence.
Main Results:
- Geldanamycin induced a dose-dependent G2 arrest and inhibited S phase entry.
- p53 protein accumulation increased following geldanamycin exposure, independent of DNA damage.
- Cell cycle arrest and cytotoxicity were not dependent on functional p53.
Conclusions:
- Geldanamycin induces p53 protein accumulation through a mechanism that does not involve DNA damage.
- The cell cycle arrest and cytotoxic effects of geldanamycin in A2780 cells are not mediated by p53-dependent pathways.
Related Concept Videos
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Inhibition of Cdk Activity
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...

